V-aCD3

V-aCD3 is a bispecific recombinant fusion protein designed for cancer immunotherapy. It consists of a binding domain derived from the malaria protein VAR2CSA, which selectively targets oncofetal chondroitin sulfate (ofCS) found broadly on cancer cells, linked to an anti-CD3 single-chain variable fragment that recruits and activates T cells. This construct facilitates T cell engagement with tumor cells, inducing potent antitumor cytotoxicity and immune activation. The molecule can be engineered to recognize either murine or human CD3, with murine-specific versions used in preclinical mouse models and human-specific versions under development. Combination with immune checkpoint inhibitors converts immunologically “cold” tumors into “hot,” resulting in complete regression and lasting immune memory. It is in preclinical and early-stage development as a broad therapeutic strategy for various solid tumors.[1][3]

Other names

V-aCD3V-aCD-3V-aCD 3rVAR2-anti-CD3 bispecificrVAR-2-anti-CD3 bispecificrVAR 2-anti-CD3 bispecificVAR2CSA-anti-CD3 bispecificVAR-2CSA-anti-CD3 bispecificVAR 2CSA-anti-CD3 bispecific